ARTICLE | Clinical News
SDP051: Phase I data
February 10, 2014 8:00 AM UTC
A placebo-controlled Phase I trial in healthy volunteers showed that single ascending-doses of SDP051 were well tolerated up to 10 mg/kg with no evidence of significant adverse events. Next year, Adhe...